Horvat Joao V, D'Alessio Donna D, Bernard-Davila Blanca, Martinez Danny F, Morris Elizabeth A
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
Clin Imaging. 2018 Nov-Dec;52:79-87. doi: 10.1016/j.clinimag.2018.06.012. Epub 2018 Jun 28.
To determine if real-time breast ultrasound (RTUR) after second opinion reinterpretation of submitted static ultrasound images at a comprehensive cancer center impacts clinical management, specifically by detecting additional cancer and preventing unnecessary biopsy.
In this IRB-approved and HIPAA-compliant retrospective study, 209 patients were included who had breast ultrasound studies from outside facilities submitted for second opinion review between January 2013 and May 2014, and who subsequently underwent RTUR at our institution within three months of the outside study. Findings on submitted exams were compared with those on RTUR and disagreements between them were annotated to indicate the presence or absence of suspicious lesions and recommendation for biopsy. Changes in management were defined as any additional biopsies performed or biopsies averted after RTUR and reported as frequencies and percentages using 95% confidence intervals.
Following RTUR, 49 additional biopsies were performed in 43/209 patients (20.6%; 95% CI 15.1-26.1%). Additional cancer was found in 12/49 (24.5%) biopsies in 11/209 patients (5.3%; 95% CI 2.2-8.2%). Forty biopsies in 31/209 (14.8%; CI 10.0-19.7%) patients originally recommended were canceled after RTUR. Overall, a change in management after RTUR was observed in 68/209 patients (32.5%; 95% CI 26.1-38.9%), including patients with either additional biopsies performed or biopsies averted.
RTUR was found to be an important tool in the management of patients at our comprehensive cancer center. Although additional false-positive lesions may be detected on RTUR, a great number of patients will benefit from RTUR in finding additional cancers or avoiding unnecessary biopsies.
确定在综合癌症中心对提交的静态超声图像进行二次解读后的实时乳腺超声(RTUR)是否会影响临床管理,特别是通过检测出额外的癌症并避免不必要的活检。
在这项经机构审查委员会(IRB)批准且符合健康保险流通与责任法案(HIPAA)的回顾性研究中,纳入了209例患者,这些患者在2013年1月至2014年5月期间提交了来自外部机构的乳腺超声检查以供二次解读,随后在外部检查后的三个月内在我们机构接受了RTUR。将提交检查的结果与RTUR的结果进行比较,并对两者之间的分歧进行标注,以表明可疑病变的存在与否以及活检建议。管理上的变化定义为RTUR后进行的任何额外活检或避免的活检,并使用95%置信区间报告为频率和百分比。
RTUR后,43/209例患者(20.6%;95%CI 15.1 - 26.1%)进行了49次额外活检。在11/209例患者(5.3%;95%CI 2.2 - 8.2%)的12/49次(24.5%)活检中发现了额外的癌症。RTUR后,31/209例(14.8%;CI 10.0 - 19.7%)患者原本建议的40次活检被取消。总体而言,68/209例患者(32.5%;95%CI 26.1 - 38.9%)在RTUR后出现了管理上的变化,包括进行了额外活检或避免了活检的患者。
发现RTUR是我们综合癌症中心患者管理中的一项重要工具。虽然RTUR可能会检测到额外的假阳性病变,但大量患者将从RTUR中受益,可发现额外的癌症或避免不必要的活检。